로딩 중…
지수 로딩 중…
Niagen Bioscience Inc
NAGE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$2.41+3.43%
2026-11-02
Financials
Valuation Metrics
Niagen Bioscience Inc's Market Cap is $192M. At end of 2025 it was $502M. Ranked #2997 of 3,118 in US market (top 96%), #1372 of 1,474 on NASDAQ (top 93%), #248 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $192M | US#2,997/3,118 Sec#248/265 |
| Revenue | $129M | US#2,625/3,118 Sec#118/265 |
| Net Income | $16M | US#2,112/3,118 Sec#68/265 |
| Total Assets | $107M | US#3,048/3,118 Sec#259/265 |
| Net Assets | $83M | US#2,813/3,118 Sec#215/265 |
| Employees | 117 | US#2,582/3,118 Sec#165/265 |
| Value | ||
| P/E | 12.00x | US#501/3,118 Sec#15/265 |
| P/B | 2.33x | US#1,430/3,118 Sec#73/265 |
| P/S | 1.49x | US#1,001/3,118 Sec#16/265 |
| EV/EBITDA | 6.90x | US#353/3,118 Sec#12/265 |
| FCF Yield | 2.96% | US#1,813/3,118 Sec#54/265 |
| Profitability | ||
| ROE | 19.38% | US#618/3,118 Sec#33/265 |
| ROA | 15.00% | US#234/3,118 Sec#27/265 |
| Op. Margin | 6.67% | US#1,836/3,118 Sec#68/265 |
| Revenue Growth | 10.99% | US#1,168/3,118 Sec#92/265 |
| Earnings Growth | -9.80% | US#1,443/3,118 Sec#36/265 |
| Financial Health | ||
| Debt Ratio | 29.16% | US#327/3,118 Sec#103/265 |
| Total Debt | $2M | US#2,936/3,118 Sec#231/265 |
| FCF | $6M | US#2,248/3,118 Sec#85/265 |
| Cash | $67M | US#2,445/3,118 Sec#206/265 |
| Current Ratio | 6.50x | US#371/3,118 Sec#117/265 |
| Net Debt/EBITDA | -3.49x | US#99/3,118 Sec#6/265 |
| Performance | ||
| 1Y Return | -68.04% | US#3,022/3,118 Sec#253/265 |
| 1M Return | -13.62% | US#2,797/3,118 Sec#226/265 |
| From 52W High | -69.69% | US#2,975/3,118 Sec#240/265 |
| 1Y MDD | -67.55% | US#2,889/3,118 Sec#230/265 |
| Trading | ||
| Volume | 487,697 shares | US#2,130/3,118 Sec#205/265 |
| Trading Value | $1M | US#2,994/3,118 Sec#255/265 |
| Per Share | ||
| EPS | $0.20 | US#2,026/3,118 Sec#67/265 |
| BPS | $1.04 | US#2,687/3,118 Sec#201/265 |
Company Info
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.